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Texture analysis of 125I-A5B7 anti-CEA
antibody SPECT differentiates metastatic
colorectal cancer model phenotypes and
anti-vascular therapy response
V Rajkumar1, V Goh2, M Siddique2, M Robson1, G Boxer1, R B Pedley1,3 and G J R Cook*,2,3
1UCL Cancer Institute, University College London, 72 Huntley St, London WC1E 6BT UK and 2Division of Imaging Sciences and
Biomedical Engineering, Kings College London, St Thomas’ Hospital, Westminster Bridge Road, London SE1 7EH, UK
Background: We aimed to test the ability of texture analysis to differentiate the spatial heterogeneity of 125I-A5B7 anti-
carcinoembryonic antigen antibody distribution by nano-single photon emission computed tomography (SPECT) in well-
differentiated (SW1222) and poorly differentiated (LS174T) hepatic metastatic colorectal cancer models before and after
combretastatin A1 di-phosphate anti-vascular therapy.
Methods: Nano-SPECT imaging was performed following tail vein injection of 20MBq 125I-A5B7 in control CD1 nude mice
(LS174T, n¼ 3 and SW1222, n¼ 4), and CA1P-treated mice (LS174T, n¼ 3; SW1222, n¼ 4) with liver metastases. Grey-level
co-occurrence matrix textural features (uniformity, homogeneity, entropy and contrast) were calculated in up to three liver
metastases in 14 mice from control and treatment groups.
Results: Before treatment, the LS174T metastases (n¼ 7) were more heterogeneous than SW1222 metastases (n¼ 12) (uniformity,
P¼ 0.028; homogeneity, P¼ 0.01; contrast, P¼ 0.045). Following CA1P, LS174T metastases (n¼ 8) showed less heterogeneity than
untreated LS174T controls (uniformity, P¼ 0.021; entropy, P¼ 0.006). Combretastatin A1 di-phosphate-treated SW1222 metastases
(n¼ 11) showed no difference in texture features compared with controls (all P40.05).
Conclusions: Supporting the potential for novel imaging biomarkers, texture analysis of 125I-A5B7 SPECT shows differences in
spatial heterogeneity of antibody distribution between well-differentiated (SW1222) and poorly differentiated (LS174T) liver
metastases before treatment. Following anti-vascular treatment, LS174T metastases, but not SW1222 metastases, were less
heterogeneous.
Complexity in the structure and pathophysiology, both within and
between tumours, and the heterogeneity observed in clinical
images is well recognised. Features in clinical images are
a reflection of the underlying cellular and molecular characteristics
of tumours including cell proliferation and metabolism, necrosis,
fibrosis, differences in blood flow and angiogenesis, hypoxia and
expression of specific receptors and antigens (Lankester et al, 2007;
Henriksson et al, 2007; Ganeshan et al, 2013). Within any medical
image, including computed tomography (CT), magnetic resonance
imaging, positron emission tomography, single photon emission
computed tomography (SPECT) and ultrasound, texture features,
describing relationships between grey-level intensity and position
of pixels, can be extracted, quantified and linked to underlying
biological complexity and heterogeneity (Castellano et al, 2004;
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Asselin et al, 2012; Davnall et al, 2012; Chicklore et al, 2013). The
biological processes reflected in image heterogeneity remain
hypothetical, but there is growing evidence that the measurement
of heterogeneity in medical images by textural analysis may allow
better tissue characterisation, image segmentation, and prediction
of therapy response and survival (Al-Kadi and Watson, 2008; Eary
et al, 2008; Yu et al, 2009; El Naqa et al, 2009; Goh et al, 2009;
Tixier et al, 2011; Goh et al, 2011; Cook et al, 2013; Parikh et al,
2014). Second-order statistical based techniques have been most
commonly applied, reflecting the local spatial distribution of voxel
values, calculating local features at each voxel within the in-plane
image and deriving parameters from the distributions of the local
features. A number of texture features can be derived that provide
a measure of intralesional heterogeneity (Haralick et al, 1973;
Tixier et al, 2011; Davnall et al, 2012).
Single photon emission computed tomography imaging is
critical for successful planning and monitoring of antibody-
targeted radionuclide imaging and therapy (radioimmunotherapy).
For example, imaging with 111In-ibritumomab tiuxetan is used to
determine whether there is sufficient and uniform antibody
retention within the tumour prior to 90Y-ibritumomab tiuxetan
radioimmunotherapy, and ultimately determines eligibility for
treatment. Longitudinal SPECT imaging is also used to
monitor antibody biodistribution and dosimetry in patients,
for example, receiving anti-carcinoembryonic antigen (CEA)
131I-A5B7 antibody in combination with the vascular disrupting
agent (VDA), combretastatin A4-phosphate (Meyer et al, 2009).
Texture analysis would be able to augment current methods by
quantifying the heterogeneity of antigen distribution non-inva-
sively with imaging, before and after therapy. This would have
utility in future clinical trials, potentially giving insight into the
resistance of some tumours to antigen-targeted therapy and
providing non-invasive imaging biomarkers of tumour phenotype
and therapy response.
In this pre-clinical study, we set out to assess the changes in
heterogeneity of CEA expression in 125I-A5B7 SPECT images of
two contrasting (well-differentiated and poorly differentiated)
human colorectal liver metastatic models, before and after therapy
with a VDA, combretastatin A1 di-phosphate (CA1P, OXi4503).
This drug produces a rapid reduction in tumour blood flow,
leading to massive central necrosis by 24 h, but leaving a viable rim
of cells at the periphery, which can continue to grow. Our
hypotheses were that texture analysis of 125I-A5B7 antibody
distribution by SPECT could reveal different characteristics
between the two contrasting tumour models and that differences
in textural features would exist between treated and untreated liver
metastases. Thus, the aim of the study was to test the ability of
texture analysis to differentiate the spatial heterogeneity of
125I-A5B7 anti-CEA antibody distribution by nano-SPECT
imaging in well-differentiated (SW1222) and poorly differentiated
(LS174T) hepatic metastatic colorectal cancer models before and
after CA1P anti-vascular therapy.
MATERIALS AND METHODS
Animal studies. The UK Coordinating Committee on Cancer
Research Guidelines for the Welfare of Animals in Experimental
Neoplasia and the Animal (Scientific Procedures) Act 1986 were
followed for all of the animal experiments (Workman et al, 1988).
The study was reviewed and approved by the UCL Animal Welfare
and Ethical Review Body (AWERB) under project licence 70–309.
Food and water was available ad libitum, the water containing 0.1%
potassium iodide to block thyroid uptake of iodine.
Metastatic liver models. Two CEA-producing, human colorectal
adenocarcinoma cell lines, LS174T and SW1222 (El Emir et al, 2007),
were used to develop liver metastatic models in female nude CD1
mice (6–8-weeks old, 20–25 g) which were purchased from Charles
River and acclimatised for a week prior to initiation of studies.
Mice were housed under sterile conditions in individually
ventilated cages, fed with standard chow diet and water ad libitum,
and maintained on an automatic 12 h light cycle at 22–24 1C. These
models were selected to provide different pathophysiologies. The
LS174T is a moderate to poorly differentiated tumour, with
heterogeneous CEA distribution with greatest expression on
perivascular tumour cells. The SW1222 tumour is well-differen-
tiated. Carcinoembryonic antigen expression is mainly restricted to
the luminal surface of cells surrounding each gland and presents
a more homogeneous pattern than LS174T (El Emir et al, 2007).
LS174T and SW1222 cells were grown as an adhesion culture
in Eagle’s Minimal Essential medium supplemented with 10%
FCS, 2mmol l 1 L-glutamine, 1% non-essential amino acids
(all media components purchased from PAA Laboratories, Yeovil,
UK). Sub-confluent cells in logarithmic growth were trypsinised
(Trypsin-EDTA, PAA Laboratories), counted and re-suspended in
serum-free medium at the required concentration for setting up the
models. Mice were anaesthetised using isoflurane and the abdomen
was swabbed using chlorhexidine. Subcutaneous Buprenorphine
analgesic was administered locally. The spleen was exteriorised
through a vertical 1–1.5 cm subcostal incision in the left
abdominal wall. Cells (1 106 in 0.1ml) were injected. After
2–3min, the splenic vessels were tied off using a suture and the
spleen was removed. The inner wound was closed using Vicryl-40
stitches and the outer wound was closed using metal clips, which
were removed after 9 days. Three LS174T and four SW1222
bearing mice were used as untreated controls. Three LS174T and
four SW1222 bearing mice were treated with the VDA, CA1P.
Drug administration. Combretastatin A1 di-phosphate, provided
by OXiGENE (San Francisco, CA, USA), was made up in sterile
saline and 10mg kg 1 injected intraperitoneally 48 h before
antibody administration.
Antibody radiolabelling. A5B7, a monoclonal anti-CEA antibody
(UCB-Celltech, Slough, UK), was used for biodistribution studies.
This antibody and its fragments are in regular preclinical and
clinical use, and have been extensively used in clinical radio-
immunotherapy and combined anti-vascular studies (El Emir et al,
2007; Meyer et al, 2009). A5B7 was labelled with 125I (Perkin
Elmer, Boston, MA, USA) using the Iodogen method as previously
described (El Emir et al, 2007; Folarin et al, 2010). Briefly, 125I and
A5B7 were mixed at a ratio of 5:1 in Iodogen tubes (Pierce,
Loughborough, UK) for 20min. The mixture was then loaded onto
a PD-10 desalting column (GE Healthcare, Amersham, UK) and
radiolabelled antibody was eluted with PBS. Thin layer chromato-
graphy was used to assess radiopharmaceutical purity (silica gel
Si60, stationary phase and 80% methanol, mobile phase).
Small animal SPECT/CT imaging. LS174T (n¼ 3) and SW1222
(n¼ 4) tumour-bearing CD1 nude mice were used as untreated
controls. LS174T (n¼ 3) and SW1222 (n¼ 4) mice were treated
with CA1P (10mg kg 1 i.p.). After 48 h, the radiolabelled antibody
was administered to the mice (0.1ml in sterile saline, 20MBq,
25 mg 1 protein per mouse) via the tail vein. After a further 48 h
the mice were anesthetised by inhalation of 2% isoflurane in
oxygen and imaged with a NanoSPECT/CT small animal imager
(Mediso Imaging Systems, Budapest, Hungary) for 2 h using a
multi-pinhole (nine pinholes, aperture 1.0mm collimator and a
transaxial FOV of 62mm). A total of 24 projections were acquired
in a 256 256 matrix with a minimum of 10 000 counts per
projection. Single photon emission computed tomography images
were reconstructed with Hi SPECT software using a dedicated
ordered subset-expectation maximisation algorithm (Scivis, Go¨t-
tingen, Germany). Computed tomography images (240 projections,
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1 second, 55 kVp) were acquired prior to SPECT imaging. The
SPECT and CT fusion images were obtained using the automatic
fusion feature of the InVivoScope software (Bioscan Inc.,
Washington, D.C., USA).
Texture analysis. Regions of interest were drawn manually
around up to three of the largest liver metastases in each of the 14
mice on each transaxial slice of 125I-A5B7 SPECT images in
which the tumours were visible. Metastases greater than 0.3 cm in
diameter were selected to minimise potential partial volume
effects on analysis. The range in diameter for the selected lesions
was 0.31–1.02 cm (mean ¼ 0.51 cm). Second-order, statistical
based texture features were calculated from grey level co-
occurrence matrices (GLCM) which measure the grey-level
distribution of pairs of voxels (Haralick et al, 1973). This method
summarises the distribution of neighbouring pairs of voxels in 13
orientations and two directions, the voxel size being 0.3
0.3 0.3mm. Calculation of the textural features was performed
using in-house software implemented under MATLAB
(The MathWorks Inc., Natick, MA, USA). Voxel values within
the tumour VOI were resampled to yield 32 discrete bins.
Measured parameters included uniformity (also termed angular
second moment or energy) and homogeneity, reflecting similarity
of intensities between neighbouring voxels (homogeneity para-
meters) as well as entropy and contrast, reflecting randomness
and local variations of voxel distributions, respectively (hetero-
geneity parameters) (Haralick et al, 1973) (see Appendix Table 1
for detail on texture features). These most commonly used
second-order features provide additional information on the
relationship between voxels compared with global first-order
features and have been shown to be robust in terms of
reproducibility and predictive ability (Howarth and Ruger,
2004; Tixier et al, 2012). In each of the 14 mice, regions of
interest definitions and parameter measurements were performed
again in a metastasis at a separate time point to assess
measurement variability, expressed as intraclass correlation
coefficients for each of the four texture features.
Histological analysis and CEA staining. After SPECT imaging,
the mice were killed and segments of liver containing metastatic
deposits were excised and fixed in 10% neutral buffered formalin
for at least 48 h prior to processing and paraffin embedding. Four
micrometer-thick tumour sections were stained with haematoxylin
and eosin to assess general tumour morphology. Carcinoembryo-
nic antigen immunostaining was performed using a biotinylated
version of A5B7 as previously described (El Emir et al, 2007).
High-resolution composite images of tumour sections were
acquired on an Axioimager. Z2 microscope (Carl Zeiss,
Cambridge, UK) using TissueFAXS software (TissueGnostics,
Vienna, Austria).
Statistical analysis. Statistical analyses were performed using SPSS
for Windows version 20 (IBM, Chicago, IL, USA). Differences in
textural feature values between untreated LS174T and SW1222
metastases, and between untreated and treated metastases, for both
LS174T and SW1222 metastatic models were tested using the
Mann-Whitney U test with two tailed significance at 5%.
RESULTS
Tumour size and reproducibility of measurements. No signifi-
cant difference in mean lesion diameters was found between the
two control groups (LS174T mean 0.43 cm, SW1222 mean 0.54 cm,
P¼ 0.06) or between control and treated groups (treated LS174T
mean 0.49 cm, P¼ 0.82, treated SW1222 mean 0.54 cm, P¼ 0.49).
Intraobserver variability (intraclass correlation coefficient, 95%
confidence interval) was as follows for each parameter; contrast
(0.94, 0.83–0.98), uniformity (0.98, 0.93–0.99), entropy (0.98, 0.93–
0.99) and homogeneity (0.98, 0.94–0.99).
Texture feature analysis
Control mice. In the three untreated LS174T mice, 7 metastases
were evaluable, and in the four untreated SW1222 mice,
12 metastases were selected for texture analysis. Grey level co-
occurrence matrices measures of local homogeneity (uniformity
and homogeneity) were lower in the poorly differentiated control
LS174T metastases than in the well-differentiated SW1222 lesions
(Table 1). The mean uniformity in LS174T lesions was 0.6 times
that of the SW1222 lesions (mean¼ 0.005 and 0.007 respectively,
P¼ 0.028) and the mean homogeneity was 0.8 times that of
SW1222 lesions (mean¼ 0.33 and 0.40, respectively, P¼ 0.01). As
a measure of heterogeneity, GLCM contrast was 1.7 times greater
in LS174T compared with SW1222 lesions (mean¼ 31.2 and 18.7,
respectively, P¼ 0.045). Grey level co-occurrence matrices entropy
was greater in LS174T lesions but this difference did not reach
statistical significance (mean¼ 5.7 and 5.4, respectively, P¼ 0.068).
CA1P-treated mice
LS174T metastases: For the three mice bearing LS174T tumours,
which received CA1P treatment, eight metastases were evaluable.
In these poorly differentiated lesions, GLCM features of homo-
geneity were higher following treatment than in untreated mice,
although this did not reach statistical significance for the
homogeneity parameter (Table 2). The mean uniformity was 2.2
times greater in treated compared with control lesions
(mean¼ 0.01 and 0.005, respectively, P¼ 0.021) and homogeneity














Uniformity 0.005 0.001 0.007 0.004 0.028
Homogeneity 0.33 0.04 0.40 0.07 0.01
Contrast 31.2 12.1 18.7 8.2 0.045
Entropy 5.7 0.2 5.4 0.4 0.068
Abbreviations: GCLM¼Grey level co-occurrence matrix; s.d.¼ standard deviation.
Table 2. GLCM textural features in CA1P-treated LS174T


















Uniformity 0.01 0.01 0.005 0.001 0.021
Homogeneity 0.39 0.1 0.33 0.04 0.07
Contrast 20.8 12.9 31.2 12.1 0.11
Entropy 5.3 0.4 5.7 0.2 0.006
Abbreviations: GCLM¼Grey level co-occurrence matrix; s.d.¼ standard deviation.
Table 3. GLCM textural features in CA1P-treated SW1222


















Uniformity 0.007 0.004 0.007 0.004 0.38
Homogeneity 0.39 0.09 0.40 0.07 0.41
Contrast 19.1 10.0 18.7 8.2 0.79
Entropy 5.4 0.4 5.4 0.4 0.98
Abbreviations: GCLM¼Grey level co-occurrence matrix; s.d.¼ standard deviation.
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1.2 times that of control lesions (mean¼ 0.39 and 0.33,
respectively, P¼ 0.07). Grey level co-occurrence matrices features
of heterogeneity were lower in treated lesions although this was
only statistically significant for entropy. The mean entropy in
treated lesions was 0.9 times that of control lesions (mean¼ 5.3
and 5.7, respectively, P¼ 0.006) and contrast 0.7 times that of
control lesions (mean¼ 20.8 and 31.2, respectively, P¼ 0.11).
SW1222 metastases: For the four mice bearing SW1222 tumours,
which received CA1P treatment, 11 metastases were selected for
texture analysis. In these well differentiated lesions, the treated
metastases showed no significant difference in texture of hepatic
metastases compared with controls (n¼ 12) for any of the GLCM
features (Table 3).
Representative SPECT images of intrahepatic metastases from
both SW1222 and LS174T are shown in Figure 1.
Histological analysis. Histological analysis confirmed that control
LS174T and SW1222 sections demonstrated a typical morphology
and pattern of CEA expression (El Emir et al, 2007). SW1222
tumour deposits were organised into highly differentiated viable
glandular structures (Figure 2A). Carcinoembryonic antigen
expression was limited to the apical surface of cells surrounding
each gland and was uniformly expressed throughout the tumour
(Figure 2E). LS174T tumours displayed moderate to poor
differentiation with little evidence of glandular structures
(Figure 2C). Expression of CEA was heterogeneously distributed
throughout the tumour, with the expression being most pre-
dominant on perivascular tumour cells (Figure 2G). Treatment
with CA1P in both SW1222 and LS174T tumours resulted in the
development of a central necrotic core with only a peripheral rim
of viable tumour cells remaining (Figure 2B and D), which were
shown to express CEA (Figure 2F and H).
DISCUSSION
Texture analysis of SPECT images of 125I-A5B7 anti-CEA antibody
shows the distribution is more heterogeneous in an untreated
poorly differentiated human colorectal metastatic model (LS174T)
than in a model with a well-differentiated glandular structure
(SW1222). This result is in agreement with previous observations
for subcutaneous models of LS174T and SW1222 xenografts when
measured by three-dimensional microvascular corrosion casting,
high resolution multifluorescence microscopy and transmission
electron microscopy (El Emir et al, 2007; Folarin et al, 2010;
Rajkumar et al, 2014) which showed that vascular supply, tumour
structure and antigen distribution varied greatly between the two
models.
Measurement of all texture parameters showed good reprodu-
cibility with intraclass correlation coefficients ranging from 0.94 for
contrast to 0.98 for uniformity, entropy and homogeneity.
The most relevant factor for our study is the difference in
antigen distribution between the two models. In the LS174T model,
CEA is distributed very heterogeneously, but with greatest
expression on perivascular tumour cells, while in the SW1222
model it is restricted to the luminal surface of the cells making up
the well-defined glands, and presents a far more homogeneous
pattern than seen in LS174T. Of relevance, the differences in CEA
distribution between the two models lead to variances in response
to therapeutic 131I-labelled A5B7 antibody, with the more
homogeneous distribution of target antigen in SW1222 leading
to superior therapeutic effect (El Emir et al, 2007). The
observations in our study support the ability of image texture
analysis to demonstrate and quantify a more uniform distribution
of antibody in one tumour model compared with another.
We have demonstrated higher homogeneity (uniformity and
homogeneity) and lower heterogeneity (contrast and entropy) of
125I-A5B7 antibody distribution in liver metastases from the poorly
differentiated LS174T model treated with the VDA CA1P
compared with untreated controls. This mathematical and
statistical description, demonstrating a change from a hetero-
geneous to a more homogeneous antibody distribution following
VDA treatment, aligns well with the features observed under the
microscope (Figure 2). Following VDA treatment, approximately
90% of the tumour cells are killed (central areas of the lesions
becoming extensively necrotic, following vascular haemorrhage),
leaving only a rim of viable tumour at the periphery of the deposit.
This is thought to be maintained by nutrients from normal blood
flow through the sinusoids of the liver. In contrast, the well-
differentiated SW1222 model showed no change in measures of
heterogeneity of antibody distribution following therapy, compared
with untreated tumours. This probably reflects the homogenous
nature of local antibody biodistribution in control SW1222
tumours, and similarly the almost entirely necrotic nature of
CA1P-treated tumours. Therefore, although the overall antibody
distribution in SW1222 tumours is restricted to a very narrow
tumour rim (1–2 cell diameters) following CA1P treatment, this is
insufficient to alter the output measure of local heterogeneity
parameters.
In order to develop this texture analysis approach in clinical
practice, there is a need to understand how the tissue structure and
cellular architecture observed on microscopy fill the volume of a
voxel generated by the clinical imaging modality, and to show how
those multiple groups of cells and tissue components generate the
relative grey-level intensities. The minimum size of tumour lesion/
regions of interest analysed (0.31 cm) consists of approximately
1000 voxels (10 10 10) each being 0.3 0.3 0.3mm. Within
an image, the associated grey-level value for each voxel is the
product of multiple types of cell (tumour cells and inflammatory
cells), connective tissue stromal elements including vessel walls,
A B
C D
Figure 1. Representative SPECT images showing the distribution of
125I-A5B7 anti-CEA in both control (A) and treated (B) SW1222 and
LS174T control (C) and treated (D) intrahepatic metastases. Visual
comparison does not reveal obvious differences between tumour types
or the effects of treatment.
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blood, body fluids and water, and for SPECT images, the relative
distribution of radiolabelled antibody. The challenge is to develop
further our understanding of how these histological features relate
to the measurements of voxel grey-level intensity.
It is now well-recognised that radiological images contain more
useful information than may be perceived by visual inspection and
that additional quantification of imaging texture features, describ-
ing the spatial distribution and heterogeneity of voxel intensities,
can augment clinical practice. There is also accumulating evidence
that parameters obtained by texture analysis, reflecting intratu-
moural heterogeneity, may yield additional predictive and
prognostic information (Al-Kadi and Watson, 2008; Eary et al,
2008; El Naqa et al, 2009; Yu et al, 2009; Goh et al, 2009, 2011;
Tixier et al, 2011; Davnall et al, 2012; Chicklore et al, 2013; Cook
et al, 2013; Parikh et al, 2014). Our preclinical imaging
observations add weight and value to this clinical approach. Both
SW1222 and LS174T intrahepatic metastases were readily detected
by SPECT imaging, however, VDA-induced changes in antibody
distribution could only be confirmed by texture analysis of the
SPECT images. To date, the biological correlates of textural
features in different types of medical imaging remain largely
unknown. It is postulated that increased image heterogeneity
within tumours may be associated with differences in regional
tumour cellularity, proliferation, hypoxia, angiogenesis and
necrosis (Henriksson et al, 2007; Ganeshan et al, 2013), factors
that independently have been associated with more aggressive
behaviour, poorer response to treatment and worse prognosis. It is
unlikely that structural (e.g., CT, magnetic resonance imaging) and
functional (e.g., positron emission tomography, SPECT) imaging
textural features are associated with the same biological causes of
spatial intensity variations within an image, although in general,
features that correspond to increased heterogeneity tend to relate
to poor prognosis and poor response to treatment.
An advantage of our current study is that we have specifically
measured the spatial distribution of antibody binding (which is
directly related to the pattern of CEA expression), rather than less
specific structural or metabolic image features, in two contrasting
human colorectal metastatic tumour models in live mice; models
for which we have prior knowledge of the likely microscopic
distribution from previous studies that used more complex
methodology directly on tumour tissue (El Emir et al, 2007).
Our study shows the potential for texture analysis of medical
images to non-invasively provide additional information related to
tumour phenotype and to provide novel quantitative imaging
biomarkers that may predict or measure treatment response to
radioimmunotherapy. Patients who are treated with radioimmu-
notherapeutics may have a SPECT scan prior to treatment with
radiolabelled antibody with the possibility of a series of SPECT
scans during therapy as the bound radiolabelled antibody persists
in the tumour over time. The data from these reconstructed images
can be used to estimate the dose distribution that the patient is
receiving, but in addition, have the potential to provide informa-
tion about how the cancer is responding and also how the
distribution of the antigen target that is remaining in dead or dying
tumour deposits is changing. Although 125I-iodine is routinely used
for pre-clinical SPECT imaging, and in our hands generated good
quality SPECT images, the low energy gamma rays of 125I-iodine
render it unsuitable for quantitative SPECT imaging because of
attenuation and scattering. We therefore envisage that further
translation of these studies into the clinic will require the use of
alternative isotopes such as 123I-iodine for SPECT or 124I-iodine for
positron emission tomography. This study demonstrates the
complexity involved in texture analysis, and supports the need
for further correlative studies in order to determine the biological
correlates of heterogeneity in other radiological imaging methods,
and to further investigate the potential use of texture analysis
methods in the development of novel imaging biomarkers.
In conclusion, texture analysis of 125I-A5B7 SPECT is able to
measure the greater spatial heterogeneity of CEA distribution in
poorly differentiated liver metastases and a reduction in hetero-
geneity after anti-vascular treatment in these poorly differentiated
tumours.
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Figure 2. Representative haematoxylin and eosin (A–D) and anti-CEA immunohistochemical (E–H) micrographs demonstrating the effect of
CA1P on the distribution of viable cells and CEA in SW1222 (A, B, E, F) and LS174T (C, D, G, H) intrahepatic metastases. Control SW1222
metastases are almost totally viable (arrow, A), with relatively uniform expression of CEA (arrow, E). After treatment with CA1P, viable CEA-
expressing tumour cells are restricted to the peripheral rim (arrow, B and F). In control LS174T metastases (C), CEA expression (arrow, G) is more
heterogeneous than in SW1222 metastases (E). After treatment with CA1P (D), viable and CEA-expressing tumour cells are similarly restricted to
the peripheral rim (arrows, D and H).
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APPENDIX 1







i, j is the voxel value in region of interest and p(i,j) the probability
of the occurrence of that voxel value.
Measures the sum of squared elements in the matrix.

















p i; jð Þ;where ijj j ¼ n
( )
Ng - number of distinct grey levels in the quantised image
Measures contrast or local intensity variation and favours contributions from





p i; jð Þ log p i; jð Þ  A measure of randomness. Inhomogeneous textures have high entropy,
whereas homogeneous textures will have low entropy.
Texture analysis of 125I-A5B7 anti-CEA antibody SPECT BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.166 1887
